Altre lingue Ocumension Therapeutics

Azioni

1477

KYG674111011

Tempo differito Hong Kong S.E. Altri mercati azionari 08:01:53 25/04/2024			Variaz. 5gg	Var. 1 gen.
5,98 ^HKD	-0,83%		-3,10%	-11,23%

15/04	Ocumension Therapeutics annuncia la sperimentazione clinica di Fase III di OT-502 in Cina	CI
08/04	Il farmaco oculare di Ocumension Therapeutics completa gli studi clinici e presto presenterà domanda di NDA	MT

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Ocumension Therapeutics Completes Phase III Trials for Postoperative Inflammation Drug	15/04
Ocumension Therapeutics Announces Phase III Clinical Trial of OT-502 in China	15/04
Ocumension Therapeutics' Eye Drug Completes Clinical Trials, to Apply for NDA Soon	08/04
Ocumension Therapeutics Announces Completion of the Phase III Clinical Trial of OT-702 in China	08/04
Ocumension Therapeutics’ Loss for 2023 Narrows; Shares Down 4%	22/03
OcuMension (01477.HK) Invests Over RMB 123.8 Million in Research, Technology and Self-development Progress in Tandem, Main Product Sales Show Comprehensive Growth	21/03
Ocumension Therapeutics Reports Earnings Results for the Full Year Ended December 31, 2023	21/03
Ocumension Therapeutics' Phase 2 Trial for Dry Eye Treatment Meets Clinical Endpoints	14/03
Ocumension Therapeutics Announces Phase II Clinical Trial of OT-202	14/03
Ocumension Therapeutics Cuts Shareholding in Nasdaq-Listed EyePoint Pharmaceuticals	17/01
Ocumension Therapeutics Gets Nod to Register Iluvien in Hong Kong	20/12
Ocumension Therapeutics Receives Approval for Marketing OT-703 in Hong Kong	20/12
Ocumension Therapeutics commences an Equity Buyback for 69,071,128 shares, representing 10% of its issued share capital, under the authorization approved on June 16, 2023.	13/12
Ocumension Says Core Product Added to China's National Reimbursement Drug List	13/12
China Includes Ocumension's Middle Eye Infection Treatment in Drug Reimbursement List	13/12
Eyepoint Pharmaceuticals Insider Sold Shares Worth $19,510,637, According to a Recent SEC Filing	08/12
Ocumension Therapeutics Completes Patient Enrollment for Post-Operative Inflammation Drug in China	30/11
Ocumension Therapeutics Completes Enrollment in the Phase Iii Clinical Trial of OT-502 in China	29/11
Ocumension Therapeutics Plans HK$100 Million Share Buyback	29/11
Ocumension Enrolls 213 Patients for Phase II Trial of Eye Medication in China	22/11

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Ocumension Therapeutics

Azioni

1477

KYG674111011

Altre lingue

Filtri